UBX-0101 Drug Asset Due Diligence Report 2026

This UBX-0101 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether UBX-0101 can convert its Small molecule drug profile and MDM2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	UBX-0101 (query alias: UBX-0101)
Modality / target	Small molecule drug; MDM2; MDM2 inhibitors
Highest global status	Phase 2
Originator	Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
Active developers	Jiangsu Yasheng Pharmaceutical Development Co. Ltd.

The MCP disease footprint includes Osteoarthritis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04229225	Phase 1	Completed	35	Primary endpoint not disclosed in English source
NCT04129944	Phase 2	Completed	183	Primary endpoint not disclosed in English source
NCT03513016	Phase 1	Completed	78	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Therapeutic subtypes of knee osteoarthritis: differential treatment effects among predicted endotypes in past clinical trials

Phase 2/3; n=1466; evaluation: Positive. Reported fields: NRS knee pain(26-week) = -6.46 % ( -16.23 to 3.31); WOMAC pain(two-year) = -6.19 % ( -10.55 to -1.83)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee

Phase 2; n=183; evaluation: Not stated in English source. Reported fields: Baseline(Mean) = 2.20 Point ; Baseline(Mean) = 2.05 Point

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

UBX-0101 addresses Osteoarthritis. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 16 matched transaction record(s) under the scope “target-level comparable: MDM2.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: MDM2 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-29	Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline	Phase 3	US$450.0M upfront; US$1,300.0M milestones
2025-04-24	Mosaic Therapeutics In-Licenses Two Clinical-Stage Oncology Programs From Astex Pharmaceuticals for Development as Proprietary Combination Therapies	Phase 2	Financial terms not disclosed
2024-10-31	Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma	Clinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Senotherapy for treating and preventing neurodegenerative disease”. The milestone feed surfaced a patent-application signal described as “Bionic nano-drug delivery carrier for targeting cartilage cells as well as preparation method and application of bionic nano-drug delivery carrier”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO